Please login to the form below

Biogen

This page shows the latest Biogen news and features for those working in and with pharma, biotech and healthcare.

Biogen just can’t quit Alzheimer’s, licensing another drug from Pfizer

Snaps up clinical-stage candidate for $75m upfront. Biogen’s mixed fortunes in Alzheimer’s drug development haven’t stopped it snapping up a clinical-stage candidate for the disease from ... The latest licensing deal adds to that pipeline and makes

Latest news

Bluebird bio launches beta thalassaemia gene therapy Zynteglo in Germany

process. This is the case for Zynteglo, which is set to undergo the NICE STA process – Biogen’s spinal muscular atrophy (SMA) treatment Spinraza (nusinersen) also followed this pathway, and was
The year in review

The Alzheimer’s community is looking towards a big year in 2020 with the late-year news that Biogen will submit a Biologics License Application for aducanumab and the news that
Intra-Cellular soars on FDA approval of schizophrenia drug

This includes Sage Therapeutics, Acadia Pharmaceutical, Karuna Therapeutics and even Biogen, which is looking for approval of its controversial Alzheimer’s drug.
Biogen bets on Ionis’ early-stage Alzheimer’s drug

However, according to Biogen, analysis of patients treated at the higher-dose were promising enough to warrant an application to the FDA. ... In a much-anticipated presentation delivered earlier this month, Biogen unveiled a fresh look at the ENGAGE and
Biogen defends aducanumab filing plan amid scepticism

A new look at pivotal trial data described as hard-to-interpret. A much-anticipated presentation of data from Biogen’s pivotal trials programme for Alzheimer’s disease candidate aducanumab has ... He noted however that Biogen is collecting more data

More from news
Approximately 118 fully matching, plus 298 partially matching documents found.

Latest Intelligence

The changing nature of approvals – what does the future hold?

the phases of development represented in the analysis and, until the recent about-turn by Biogen, the outlook for neuroscience was bleak.
Detecting Alzheimer’s ahead of a cure

Biogen and Eisai also pulled the plug on their Alzheimer’s drug aducanumab, after advice from an independent data monitoring committee forced them to abandon the phase 3 Abeta-targeting candidate.
Bluebird: on a mission to ‘recode’ the DNA of healthcare

Nightstar was bought by Biogen for $800m in March.
#OrkambiNow?

But Orkambi is not the only orphan disease drug stuck in market access limbo in the England – Biogen’s Spinraza and BioMarin’s Kuvan are both currently suffering similar fates, and
Where next in Alzheimer’s disease R&D?

Another crushing blow to hopes came on 21 March, when Biogen and Eisai pulled the plug on their phase 3 Abeta-targeting aducanumab. ... N.B. This article was updated on 21 March 2019 following news of Biogen and Eisai's termination of the aducanumab

More from intelligence
Approximately 1 fully matching, plus 40 partially matching documents found.

Latest appointments

BMS appoints new commercial leader, Davies joins Eisai and more

operations. She joins Sobi from Biogen, where she served as vice president for global supply chain operations and strategic partnerships.
Biogen appoints executive VP, corporate development

Biogen has appointed Daniel Karp as its executive vice president, corporate development effective 11 June. ... He will also become a member of the executive committee and will report directly to chief executive officer Michel Vounatsos, who said: “We
Gamida Cell strengthens leadership team

Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at the company, activities he has practised during his time with Biogen, Amgen and Novartis.
Editas Medicine names James Mullen as chairman

Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.
Acumen appoints new strategy director

Thomas Bols will focus on reinforcing Acumen’s healthcare practice

More from appointments
Approximately 16 fully matching, plus 32 partially matching documents found.

Latest from PMHub

Article: Market access in Brazil

In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde
Healthcircle

Biogen. Chugai. Eisai. Helsinn. Ipsen. Johnson &Johnson. Lundbeck. Medtronic. Mentholatum. Novartis.
Attigo (part of the Mednet Group)

Alzheimer’s Research UK. Alzheimer’s Society. Basic Needs. Biogen. Butterfly Scheme. Cardiomyopathy UK.
IGNIFI

Allergan. Biogen. Boehringer Ingelheim. CO.DON. Danone Nutricia. Ferring Pharmaceuticals. Kyowa Kirin.
Wallace Health

Our expertise spans healthcare providers, pharmaceuticals and consumer health and we work for clients including HCA Hospitals, Alliance Medical, GSK and Biogen as well as high-performing start-ups such as

More from PMHub
Approximately 1 fully matching, plus 12 partially matching documents found.

Featured jobs

Director of Scientific Services, Medical Communications, Six fig...: Six figure salary

Account Director or Senior Account Director: Salary TBC

Senior Medical Writer, MedComms Agency: Salary TBC

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Vice President: Competitive Salary Offered

Account Manager– Medical Communications: (Negotiable - depending on experience)

Consultant: competitive salary

Principal Medical Writer: £48 - 58, 000 according to skills and experience benefits

Subscribe to our email news alerts

PMHub

Add my company

AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...